Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) CFO Emma Reeve Sells 4,010 Shares


Share on StockTwits

Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) CFO Emma Reeve sold 4,010 shares of Constellation Pharmaceuticals stock in a transaction dated Friday, February 19th. The stock was sold at an average price of $37.71, for a total transaction of $151,217.10. Following the transaction, the chief financial officer now directly owns 4,010 shares in the company, valued at $151,217.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Emma Reeve also recently made the following trade(s):

  • On Monday, February 22nd, Emma Reeve sold 6,260 shares of Constellation Pharmaceuticals stock. The shares were sold at an average price of $37.60, for a total transaction of $235,376.00.
  • On Monday, December 21st, Emma Reeve sold 5,720 shares of Constellation Pharmaceuticals stock. The shares were sold at an average price of $35.11, for a total transaction of $200,829.20.

Shares of CNST stock traded down $0.47 during trading on Tuesday, reaching $36.31. The company’s stock had a trading volume of 566,220 shares, compared to its average volume of 448,241. The company has a debt-to-equity ratio of 0.05, a current ratio of 15.81 and a quick ratio of 15.81. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of -13.40 and a beta of 2.80. The stock’s 50-day moving average price is $32.82 and its 200 day moving average price is $26.28. Constellation Pharmaceuticals, Inc. has a 1-year low of $17.00 and a 1-year high of $50.90.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 price target for the company in a research report on Thursday, October 29th. BMO Capital Markets upgraded shares of Constellation Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $27.00 to $50.00 in a research report on Monday, January 25th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $43.50.

Several hedge funds have recently made changes to their positions in CNST. Penserra Capital Management LLC acquired a new position in shares of Constellation Pharmaceuticals in the fourth quarter valued at approximately $31,000. Pacer Advisors Inc. acquired a new position in shares of Constellation Pharmaceuticals in the third quarter valued at approximately $35,000. Accel Wealth Management acquired a new position in shares of Constellation Pharmaceuticals in the fourth quarter valued at approximately $39,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Constellation Pharmaceuticals by 165.3% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,178 shares of the company’s stock valued at $44,000 after purchasing an additional 1,357 shares in the last quarter. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of Constellation Pharmaceuticals by 152.4% in the third quarter. BNP Paribas Arbitrage SA now owns 7,924 shares of the company’s stock valued at $161,000 after purchasing an additional 4,785 shares in the last quarter.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. Its lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors.

Featured Story: What Does Beta Mean In Stock Selection?

Insider Buying and Selling by Quarter for Constellation Pharmaceuticals (NASDAQ:CNST)

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.